Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study

Study limitation reported by the research below: “The mean age at diagnosis (32.6 years) is reported, but the age range of enrolled patients is not provided, limiting age-group precision beyond 'adult'.”